Spirocyclic sulfones as gamma secretase inhibitors

Patent metadata

Field	Value
Publication number	US-9464103-B2
Application number	US-201314647769-A
Country	US
Kind code	B2
Filing date	Nov 22, 2013
Priority date	Nov 29, 2012
Publication date	Oct 11, 2016
Grant date	Oct 11, 2016

Abstract

Disclosed herein are compounds of Formula (I), wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

First claim

What is claimed:

1. A compound of the Formula (I):

wherein:
A is a 4 to 7 membered spirocyclic ring comprising at least one heteroatom selected from the group consisting of N, O, S, S(O) 2 , P(O)R 1 , and N—S(O) 2 —R 1 , wherein the spirocyclic ring is optionally substituted with 1 to 3 substituents selected from the group consisting of C1-3alkyl and ═O, with the proviso that A is not 1,3-dioxolane;
R 1 is C1-6alkyl optionally substituted with halo;
Each L 1 is independently selected from the group consisting of 1) C1-3alkyl optionally substituted with halo, and 2) halo;
Each L 2 is independently selected from the group consisting of 1) C1-3alkyl optionally substituted with halo, and 2) halo; and
n is selected from 0 to 3 at each occurrence of n.

2. The compound according to claim 1 , wherein L 1 and L 2 are halo.

3. The compound according to claim 1 , wherein L 1 is fluoro and L 2 is chloro.

4. The compound according to claim 1 , wherein the compound is of Formula (Ia)

5. The compound according to claim 1 , wherein the compound is of Formula (II)

6. The compound according to claim 5 , wherein A is a 4 to 7 membered spirocyclic ring comprising at least one O heteroatom.

7. The compound according to claim 5 , wherein A is a 4 to 7 membered spirocyclic ring comprising one N heteroatom.

8. The compound according to claim 5 , wherein A is a 4-7 membered spirocyclic ring comprising one S heteroatom.

9. The compound according to claim 5 , wherein A is a 4-7 membered spirocyclic ring comprising one S(O) 2 heteroatom.

10. The compound according to claim 5 , wherein A is a 6-7 membered spirocyclic ring comprising two 0 heteroatoms and the heteroatom P(O)R 1 .

11. The compound according to claim 10 , wherein R 1 is methyl.

12. The compound according to claim 5 , wherein L 1 and L 2 are halo.

13. The compound according to claim 12 , wherein L 1 is fluoro and L 2 is chloro.

14. A compound which is selected from the group consisting of:

15. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising the compound according to claim 14 and a pharmaceutically acceptable carrier.

Assignees

• Merck Sharp & Dohme

Inventors

• Pissarnitski Dmitri
• Zhao Zhiqiang

Classifications

• C07D493/10

  Spiro-condensed systems · CPC title

• A61K31/353

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title

• A61K31/355

  Tocopherols, e.g. vitamin E · CPC title

• A61K31/473

  ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title